Forte Biosciences (NASDAQ: FBRX) CEO awarded options, RSUs

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Forte Biosciences, Inc. reported new equity awards to a senior executive. A Form 4 filing shows that on January 12, 2026, CEO, Secretary and Chair Paul A. Wagner received a stock option covering 270,000 shares of Forte Biosciences common stock with an exercise price of $29.66 per share. According to the vesting terms, one forty-eighth of the option vests each month after a vesting commencement date of January 1, 2026, so the option becomes fully vested after four years, as long as he continues as a service provider.

The filing also reports a grant of 180,000 restricted stock units, each representing a contingent right to receive one share of Forte Biosciences common stock. These RSUs vest in four equal annual installments on each anniversary of the same January 1, 2026 vesting commencement date, again conditioned on continued service. Following these grants, Wagner beneficially owns 270,000 stock options and 180,000 RSUs directly.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Wagner Paul A.

Role SEE REMARKS

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	270,000	$0.00	--
Grant/Award	Restricted Stock Units	180,000	$0.00	--

Holdings After Transaction: Stock Option (right to buy) — 270,000 shares (Direct); Restricted Stock Units — 180,000 shares (Direct)

Footnotes (1)

Subject to the Reporting Person continuing to be a Service Provider (as defined in the 2021 Equity Incentive Plan) through each applicable vesting date, one forty-eighth (1/48th) of the total shares subject to the option shall vest every month following the Vesting Commencement Date such that all shares shall be fully vested on the four (4) year anniversary of the Vesting Commencement Date. "Vesting Commencement Date" shall mean January 1, 2026. Each restricted stock unit ("RSU") represents a contingent right to receive one share of Forte Biosciences, Inc. (the "Issuer") Common Stock. Subject to the Reporting Person continuing to be a Service Provider (as defined in the 2021 Equity Incentive Plan) through each applicable vesting date, one fourth (1/4th) of the total RSUs subject to the award shall vest annually on the anniversary of Vesting Commencement Date such that all shares shall be fully vested on the four (4) year anniversary of the Vesting Commencement Date. "Vesting Commencement Date" shall mean January 1, 2026.

Form 4 Insider Transactions: What Each Field Means →

01/13/2026 - 04:10 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Wagner Paul A.

(Last)

(First)

(Middle)

C/O FORTE BIOSCIENCES, INC.

3060 PEGASUS PARK DR., BLDG 6

(Street)

DALLAS

75247

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Forte Biosciences, Inc. [ FBRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	SEE REMARKS

3. Date of Earliest Transaction (Month/Day/Year)
01/12/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (right to buy)	$29.66	01/12/2026		A		270,000		⁽¹⁾	01/12/2036	Common Stock	270,000	$0	270,000	D
Restricted Stock Units	⁽²⁾	01/12/2026		A		180,000		⁽³⁾	⁽³⁾	Common Stock	180,000	$0	180,000	D

Explanation of Responses:

1. Subject to the Reporting Person continuing to be a Service Provider (as defined in the 2021 Equity Incentive Plan) through each applicable vesting date, one forty-eighth (1/48th) of the total shares subject to the option shall vest every month following the Vesting Commencement Date such that all shares shall be fully vested on the four (4) year anniversary of the Vesting Commencement Date. "Vesting Commencement Date" shall mean January 1, 2026.

2. Each restricted stock unit ("RSU") represents a contingent right to receive one share of Forte Biosciences, Inc. (the "Issuer") Common Stock.

3. Subject to the Reporting Person continuing to be a Service Provider (as defined in the 2021 Equity Incentive Plan) through each applicable vesting date, one fourth (1/4th) of the total RSUs subject to the award shall vest annually on the anniversary of Vesting Commencement Date such that all shares shall be fully vested on the four (4) year anniversary of the Vesting Commencement Date. "Vesting Commencement Date" shall mean January 1, 2026.

Remarks:

CEO, Secretary and Chair of the Board

	/s/ Paul A. Wagner, Ph.D.	01/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transactions did Forte Biosciences (FBRX) disclose in this Form 4?

The Form 4 reports that CEO, Secretary and Chair Paul A. Wagner was granted a stock option for 270,000 shares of Forte Biosciences common stock at an exercise price of $29.66 per share and 180,000 restricted stock units, each representing a contingent right to receive one share of common stock.

Who is the reporting person in the Forte Biosciences (FBRX) Form 4 filing?

The reporting person is Paul A. Wagner, who is identified as a director and an officer of Forte Biosciences, Inc., with the remarks specifying that he serves as CEO, Secretary and Chair of the Board.

When were the options and RSUs granted to the Forte Biosciences (FBRX) CEO?

The stock option and restricted stock units were granted on January 12, 2026, with a vesting commencement date of January 1, 2026 for both awards.

What are the vesting terms of the 270,000 stock options reported by Forte Biosciences (FBRX)?

The 270,000-share stock option vests monthly, with one forty-eighth of the total shares vesting each month after the January 1, 2026 vesting commencement date, so that all shares are fully vested on the four-year anniversary, subject to continued service.

How do the 180,000 restricted stock units for Forte Biosciences (FBRX) vest?

The 180,000 RSUs vest in four equal installments, with one fourth of the RSUs vesting annually on each anniversary of the January 1, 2026 vesting commencement date, so they are fully vested after four years if the reporting person continues as a service provider.

How many derivative securities does the Forte Biosciences (FBRX) CEO hold after these transactions?

After the reported grants, Paul A. Wagner beneficially owns 270,000 stock options and 180,000 restricted stock units, all held directly according to the filing.